Cytokinetics Inc (CYTK) reported disappointing financial results for the third quarter of fiscal 2025, with an earnings per share (EPS) of -$2.55, falling short of Wall Street's consensus estimate of -$1.61 by $0.94. Revenue remained at $0.0 billion, matching expectations but indicating a lack of growth.
The company will host an earnings conference call to discuss these results and provide further commentary on its business performance. This update provides insight into Cytokinetics' operational challenges amid a competitive biotechnology landscape, where it focuses on developing muscle activators and inhibitors for debilitating diseases.
Cytokinetics has a market capitalization of $7,186.43 and an EPS (TTM) of -5.12. The firm is actively engaged in commercializing aficamten, a cardiac myosin inhibitor, and is also developing omecamtiv mecarbil, a cardiac myosin activator, along with other treatments for heart failure and muscular dystrophy.
Looking ahead, the company's upcoming earnings reports are scheduled for May 3, 2026, and August 4, 2026, with EPS estimates of -1.5484 and -1.579, respectively. Investors may want to review the full earnings release and management commentary for a comprehensive understanding of the company's performance and future outlook.